CKD Treatment News

Restricted access

AbbVie (North Chicago, IL) has dissolved its partnership with Reata Pharmaceuticals (Irving, TX) after nine years. The two companies were working together to develop, among other drug candidates, the therapeutic agent bardoxolone methyl for chronic kidney disease (CKD). The compound was moving along the approval pipeline until the FDA received findings that patients in the CKD treatment arm of a phase 3 study exhibited heart-related side effects, FierceBiotech.com reported.

Now the drug is being tested in more specific populations: patients with autosomal dominant polycystic kidney disease, a genetic disorder, as well as in patients with CKD caused by Alport syndrome,

Save